Aspira Women's Health Inc. is a commercial-stage diagnostics company focused on gynecological disease detection in women. The company develops and markets diagnostic tests including Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform, and OVAinform for ovarian cancer risk assessment, endometriosis, and benign pelvic mass monitoring. Operating through its laboratory subsidiary Aspira Labs, the company also offers the Aspira Synergy platform and Aspira Genetix genetic testing services.
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-04-01 | 2025-12-31 | 0000926617-26-000020 | EDGAR | 64K words |
| 2025-03-27 | 2024-12-31 | 0001641172-25-000983 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0000926617-24-000015 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000926617-23-000026 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0000926617-22-000014 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0000926617-21-000033 | EDGAR | — |
| 2020-04-07 | 2019-12-31 | 0000926617-20-000015 | EDGAR | — |
| 2019-03-28 | 2018-12-31 | 0000926617-19-000007 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0000926617-18-000012 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0000926617-17-000023 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0000926617-25-000008 | EDGAR | 28K words |
| 2025-08-13 | 2025-06-30 | 0001493152-25-011865 | EDGAR | — |
| 2025-05-19 | 2025-03-31 | 0001641172-25-011399 | EDGAR | — |
| 2024-11-19 | 2024-09-30 | 0001493152-24-046836 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096220 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060401 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000926617-23-000095 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000926617-23-000070 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000926617-23-000046 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000926617-22-000058 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000926617-22-000052 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0000926617-22-000032 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-01-30 | 0000926617-26-000007 | EDGAR | 14K words |
| 2025-12-31 | 0000926617-25-000014 | EDGAR | — |
| 2025-12-23 | 0001104659-25-124245 | EDGAR | — |
| 2025-12-22 | 0000926617-25-000010 | EDGAR | — |
| 2025-11-14 | 0000926617-25-000004 | EDGAR | — |
| 2025-10-15 | 0001493152-25-018146 | EDGAR | — |
| 2025-09-25 | 0001493152-25-014925 | EDGAR | — |
| 2025-09-18 | 0001493152-25-013987 | EDGAR | — |
| 2025-09-03 | 0001641172-25-026441 | EDGAR | — |
| 2025-08-13 | 0001493152-25-011867 | EDGAR | — |
381 total filings indexed. 349 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000926617 |
| Ticker | AWHL |
| Exchange | OTC |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report